PCRX

Pacira BioSciences, Inc.
$25.90
+0.14 (+0.54%)
Mkt Cap 1.02B
Volume 380,506
52W Range 18.8-27.66
Sector Healthcare
Beta 0.27
EPS (TTM) 0.35 USD
P/E Ratio 73.56
Revenue (TTM) 746.16M USD
Rev Growth (5Y) +11.1%
EPS Growth (5Y) -45.8%
AlphaVal · Fair Value
What we estimate one share is worth
$31.67
Fair Value moderate signal
18.2% below fair value
Modeled from cash flows & growth.
AlphaQuality · Grade
How strong & durable the business is
C-
Platform & Compounding FCF
44.6 / 100 composite
A platform business that compounds free cash flow — graded A–F vs. similar companies.

Company Description

Track Record

Showing latest 4 periods • Swipe for more
Metric 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014
Revenue 726.41M 700.97M 674.98M 666.82M 541.53M 429.65M 421.03M 337.28M 286.63M 276.37M 249.00M 197.67M
Net Income 7.03M (99.56M) 41.95M 15.91M 41.98M 145.52M (11.02M) (471,000) (42.61M) (37.95M) 1.86M (13.72M)
EPS 0.16 -2.15 0.91 0.35 0.95 3.41 -0.27 -0.01 -1.07 -1.02 0.05 -0.39
Free Cash Flow 136.66M 178.75M 139.49M 115.20M 79.85M 39.23M 60.36M 34.36M (1.48M) 8.74M (12.27M) 3.58M
FCF / Share 3.07 3.87 3.02 2.53 1.80 0.92 1.45 0.84 -0.04 0.24 -0.34 0.10
Operating CF 151.99M 189.39M 154.65M 145.27M 125.72M 77.03M 70.52M 48.87M 17.79M 33.45M 29.00M 25.47M
Total Assets 1.26B 1.55B 1.57B 1.68B 2.08B 1.27B 831.07M 689.35M 628.37M 391.47M 389.62M 326.07M
Total Debt 454.38M 638.85M 586.04M 763.39M 1.13B 541.13M 351.92M 290.93M 276.50M 108.74M 105.93M 103.10M
Cash & Equiv 158.54M 276.77M 153.30M 104.14M 585.58M 99.96M 78.23M 132.53M 54.13M 35.94M 158.97M 158.17M
Book Value 693.11M 778.35M 870.13M 775.01M 730.41M 619.69M 354.94M 321.23M 279.48M 218.98M 218.39M 171.15M
Return on Equity 0.01 -0.13 0.05 0.02 0.06 0.23 -0.03 -0.00 -0.15 -0.17 0.01 -0.08
PCRX News
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Aug 07, 2026 04:00 AM · globenewswire.com
Pacira BioSciences Announces Publication of Positive Two-Year Phase 1 Data For PCRX-201 in Annals of the Rheumatic Diseases
Aug 06, 2026 04:00 AM · globenewswire.com
Pacira Q2 Earnings & Revenues Beat, 2026 Sales Outlook Cut
Aug 05, 2026 09:21 AM · zacks.com
Pacira BioSciences, Inc. (PCRX) Q2 2026 Earnings Call Transcript
Aug 04, 2026 05:30 PM · seekingalpha.com
Pacira (PCRX) Tops Q2 Earnings and Revenue Estimates
Aug 04, 2026 02:41 PM · zacks.com
Pacira BioSciences Reports Second Quarter 2026 Financial Results
Aug 04, 2026 12:01 PM · globenewswire.com
First Trust Advisors LP Grows Position in Pacira BioSciences, Inc. $PCRX
Aug 03, 2026 01:18 AM · defenseworld.net
Pacira BioSciences Advances PCRX-201 Development Program with Successful Transition to Scalable Commercial Manufacturing Process
Jul 27, 2026 04:00 AM · globenewswire.com
Brokerages Set Pacira BioSciences, Inc. (NASDAQ:PCRX) Price Target at $29.40
Jul 25, 2026 09:59 PM · defenseworld.net
Pacira to Report Second Quarter 2026 Financial Results on Tuesday August 4, 2026
Jul 22, 2026 04:00 AM · globenewswire.com